COURT-RULING ·Filed May 5, 2026

JNJ

Janssen
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago CourtView Ruling on CourtListener
Court ruling (appellate)
Actionable Insight • Neutral

Monitor district court for consent judgment filing and any disclosed settlement terms. Given the nonprecedential nature and lack of financial details, no material stock impact expected.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d
JNJ ▲ +13.45% at T+60d
NEUTRAL call ✓ call won +13.45% · α vs SPY +10.97% · entry $225.50 → $255.82
Entry anchored
May 4, 03:59 PM ET
via exchange tick
T+1d
-0.51%
call -0.51% · α -1.89%
$224.36
settled 5mo ago
T+5d
-1.80%
call -1.80% · α -3.79%
$221.43
settled 5mo ago
T+20d
-1.16%
call -1.16% · α -6.11%
$222.89
settled 4mo ago
T+60d
+13.45%
call +13.45% · α +10.97%
$255.82
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Janssen (JNJ) and Tolmar jointly moved to remand patent infringement appeals after reaching a settlement. The Federal Circuit granted the remand, allowing the district court to enter a consent judgment. Financial terms were not disclosed, but the resolution removes litigation uncertainty for JNJ.

Court Ruling Details

Ruling Date
May 5, 2026
Court
Court of Appeals for the Federal Circuit
Court Level
Appellate
Judge
Per Curiam (Lourie, Taranto, Chen)
Case Type
patent
Ruling Type
settlement approval
Outcome
SETTLEMENT — parties reached agreement
Will It Be Appealed?
N/A (final)
Precedent Risk
LOW

Key Facts

  • Parties agreed to resolve all claims and jointly moved to remand appeals.
  • Federal Circuit remanded to district court for entry of consent judgment.
  • Order is nonprecedential and each side bears its own costs.
  • No financial terms disclosed in the order.

Financial Impact

Settlement terms undisclosed; likely immaterial given JNJ's $540B market cap.

Risk Factors

  • Settlement terms may include royalty or lump-sum payment, but likely below materiality threshold.

Market Snapshot

Price
$226.02
Volume
137
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
63% bullish (32 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-qys7383x-JNJ
16 reports for JNJ
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+60▲ +13.24%May 13, 2026
Filters
Rows
Reports for JNJ — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
Court Ruling
NEUTRAL ★ 1/10
$267.08 $267.28▲ +0.07%▲ +0.73%$258.14 (−3.35%)
Aug 18, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$273.41 $270.00▼ −1.25%▼ −0.86%$258.14 (−5.58%)
Aug 14, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$260.35 $270.24▲ +3.80%▲ +5.17%$258.14 (−0.85%)
Aug 7, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$261.81 $262.37▲ +0.21%▲ +0.26%$258.14 (−1.40%)
Aug 7, 2026
8w ago
Court Ruling
BEARISH ★ 4/10
$259.24 $260.35▼ −0.43%▼ −0.03%$258.14 (+0.42%)
Aug 4, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$254.93 $259.80▲ +1.91%▲ +2.01%$258.14 (+1.26%)
Jul 22, 2026
10w ago
Court Ruling
BEARISH ★ 7/10
$255.63 $265.53▼ −3.87%▼ −6.27%$258.14 (−0.98%)
Jul 15, 2026
11w ago
8-K
BULLISH ★ 6/10
$247.02 $255.63▲ +3.49%▲ +4.47%$258.14 (+4.50%)
May 20, 2026
19w ago
Court Ruling
NEUTRAL ★ 1/10
$229.12 $231.29▲ +0.95%▼ −0.29%$258.14 (+12.67%)
May 13, 2026
20w ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$230.79 $231.58▲ +0.34%▲ +1.06%$258.14 (+11.85%)
Showing 10 of 16

US Market Status

Market Open — Closes in 6h 23m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access